Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p483 | Paediatric bone disease | ECTS2016

Loss of type I collagen telopeptide lysyl hydroxylation causes musculoskeletal abnormalities in a zebrafish model of Bruck syndrome

Willaert Andy , Ghistelinck Charlotte , Witten P Eckhard , Huysseune Ann , Simoens Pascal , Symoens Sofie , Malfait Fransiska , De Muynck Amelie , De Paepe Anne , Kwon Ronald Y , Weiss Mary Ann , Eyre David E , Coucke Paul

Bruck syndrome, a disorder caused by bi-allelic mutations in either PLOD2 or FKBP10, is characterized by flexion contractures and bone fractures and shows strong clinical overlap with the brittle bone disease Osteogenesis Imperfecta. PLOD2 encodes the Lysyl hydroxylase 2 (LH2) enzyme, which is responsible for the hydroxylation of lysine residues in the type-I collagen telopeptides. This hydroxylation directs cross-linking of the collagen fibrils in t...

ba0007oc19 | (1) | ICCBH2019

Altered 3 hydroxylation complex in bone homeostasis

Tonelli Francesca , Leoni Laura , Cotti Silvia , Giannini Gabriella , Daponte Valentina , Gioia Roberta , Fiedler Imke , Besio Roberta , Rossi Antonio , Busse Bjorn , Witten Eckhard , Forlino Antonella

Objectives: Osteogenesis imperfecta (OI) is a heritable disorder characterized by bone deformity and skeletal fragility. Cartilage associated protein (CRTAP), proline 3-Hydroxylase 1 (P3H1) and Cyclophylin B (PPIB) are components of the endoplasmic reticulum (ER)-resident complex involved in the 3-hydroxylation of specific proline residues in collagen type I α chains. Mutations in these proteins are responsible for recessive OI type VII, VIII and IX, respectively. Murine ...

ba0004p65 | (1) | ICCBH2015

Results of a specialized rehabilitation approach in osteogenesis imperfecta

Semler Oliver , Hoyer-Kuhn Heike , Stark Christina , Schoenau Eckhard

Introduction: Osteogenesis imperfecta is a rare disease leading to immobility by recurrent fractures, immobilization, short stature and muscular weakness. Beside drug treatment and surgical procedures physiotherapy is the most important treatment approaches to increase mobility. The objective of our analysis was to evaluate the effect of a new standardized 12 months physiotherapy concept including whole body vibration over 6 months on motor function and bone mineral density in...

ba0002op4 | (1) | ICCBH2013

A new start-codon in IFITM5 causes osteogenesis imperfecta type V

Semler Oliver , Hoyer-Kuhn Heike , Garbes Lutz , Netzer Christian , Schoenau Eckhard

Background: Osteogenesis imperfecta (OI) is a rare disease characterized by increased fracture rate and bone deformities. Patients are classified by phenotype and most are affected by mutations in COL1A1/2.Patients with OI type V present with specific clinical symptoms including hyperplastic callus formation, only mildly decreased height, metaphyseal lines and a calcification of the membrane interossea of the forearm. The disease causing mutation for OI ...

ba0005p44 | Bone development/growth and fracture repair | ECTS2016

Effect of a mixture of GOS/FOS® on calcium (Ca) and phosphorus (P) absorption and bone retention in ovariectomized osteopenic rats fed a low calcium diet

Bryk Gabriel , Coronel Magali Zeni , de Portela Maria Luz Pita Martin , Zeni Susana Noemi

Dietary Ca insufficiency is a common finding, independently of socio-economic status. A low Ca intake (CaI) increases bone turnover leading to bone loss. This effect becomes more important during estrogen withdrawing. We previously found that a mixture of galactooligosaccharides (GOS) and fructooligosaccharides (FOS) enhances Ca and P absorption (Abs), being a suitable tool to optimize its bioavailability and consequently bone health. The present study evaluated the effect of ...

ba0001pp100 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

A mixture of GOS/FOS ® added to a low calcium (ca) diet improved ca, phosphorus (p) and magnesium (mg) absorption: experimental model in normal growing rats

Bryk Gabriel , Chaves Macarena Gonzales , Marotte Clarisa , Medina Daniela , Coronel Magali Zeni , de Portela Maria Luz , Zeni Susana Noemi

A mixture of Galacto-oligosaccharides (GOS) and Fructooligosaccharides (FOS) are added to commercial infant formula to promote an intestinal microbiota similar to that prevalent in breast-fed infants to improve Ca bioavailability and general health, but their mechanisms are under debate.Our objective was to evaluate the beneficial effects of the mixture of GOS/FOS added to infant formulae, on the absorption of Ca, Mg and P of a low Ca diet. Changes in in...

ba0004is18biog | (1) (1) | ICCBH2015

Management of sclerosing bone disease

Whyte Michael P

Biographical DetailsMichael P Whyte is Professor of Medicine, Pediatrics, and Genetics at the Washington University School of Medicine, a staff member of Barnes-Jewish Hospital and St. Louis Children’s Hospital, and Medical-Scientific Director at the Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children in St. Louis, Missouri, USA.<p class="abst...

ba0002oc19 | Miscellaneous | ICCBH2013

New therapeutic approach in OI VI: suppression of bone resorption using the RANKL antibody denosumab

Hoyer-Kuhn Heike , Semler Oliver , Netzer Christian , Dotsch Jorg , Schonau Eckhard

Background: Osteogenesis imperfecta (OI) as a rare disease is characterized by reduced bone mass, increased fracture rate, bone deformities and skeletal pain.Currently patients are treated with i.v. bisphosphonates regardless of the underlying mutation.Recently the gene causing OI type VI was described (SERPINF-1, altered RANKL-pathway). This leads to a new understanding of the underlying pathophysiology and offered a new therapeut...

ba0004oc7 | (1) | ICCBH2015

Osteogenesis imperfecta: a pilot trial on treatment with the RANKL-antibody denosumab

Hoyer-Kuhn Heike , Netzer Christian , Hero Barbara , Schoenau Eckhard , Semler Oliver

Osteogenesis imperfecta is a rare disease leading to multiple fractures, skeletal deformities and scoliosis due to a reduced bone mass. Pathological fractures caused by inadequate traumata are the most severe symptom. More than 85% of patients are affected by mutations in COL1A1/A2 impairing quantity and quality of collagen. At present no approved drugs for OI treatment in childhood are available. A single centre prospective pilot study was performed to assess safety and effic...